Defence Therapeutics Eases Terms on 800,000 Warrants to Boost Investor Uptake

The latest announcement is out from Defence Therapeutics ( (TSE:DTC) ).

Defence Therapeutics has amended the terms of 800,000 common share purchase warrants originally issued in a 2024 private placement, extending their expiry dates by 12 months and reducing the exercise price from $1.00 to $0.75 per share. None of the warrants have been exercised to date, and the changes, which exclude any compensation or finder warrants, remain subject to final approval by the Canadian Securities Exchange, potentially improving the attractiveness of the securities and providing added flexibility for existing warrant holders.

The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.

Spark’s Take on DTC Stock

According to Spark, TipRanks’ AI Analyst, DTC is a Neutral.

The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals are mixed with short-term stabilization but longer-term weakness, and valuation provides limited support due to negative earnings and no dividend yield.

To see Spark’s full report on DTC stock, click here.

More about Defence Therapeutics

Defence Therapeutics Inc. is a publicly traded biotechnology company focused on making cancer treatment more effective and safer. Leveraging its Accum precision intracellular drug-delivery platform, it aims to enhance the potency of antibody-drug conjugates and other complex biologics at lower doses, targeting reduced side effects and broader access to advanced therapies through collaborations with pharma and biotech partners.

Average Trading Volume: 45,460

Technical Sentiment Signal: Sell

Current Market Cap: C$34.42M

For a thorough assessment of DTC stock, go to TipRanks’ Stock Analysis page.